Search in the Abstract Database

Search Abstracts 2015

* = Presenting author

P658 Inflammatory Bowel Disease and the Risk of Other Autoimmune Diseases

J.C. Wilson*1, R. Furlano2, S. Jick3, C. Meier1, 4

1University of Basel, Department of Pharmaceutical Sciences, Basel, Switzerland, 2University Childrens Hospital Basel, University Childrens Hospital Basel,, Basel, Switzerland, 3Boston University School of Public Health, Boston Collaborative Drug Surveillance Program, Lexington, United States, 4University Hospital Basel, Basel Pharmacoepidemiology Unit, Basel, Switzerland

Background

An increased risk of autoimmune disease has been reported in patients with IBD. Using data from the Clinical Practice Research Datalink (CPRD) this study set out to further examine this relationship.

Methods

Patients with a first time IBD diagnosis were randomly matched to an equally sized IBD-free comparison group. Incidence rates for new onset autoimmune diseases were estimated. A nested case-control analysis comprising IBD patients was conducted, using conditional logistic regression to assess whether IBD severity, duration, or treatment influences the risk of developing additional autoimmune diseases

Results

During follow-up 1,069 IBD and 585 IBD free patients developed an incident autoimmune disorder. An increased incidence of autoimmune disease was observed in IBD patients (IR 9.65, 95% CI 9.09-10.24) compared to the non-IBD comparison group (IR 5.22, 95% CI 4.82-5.66). In IBD patients, increased disease severity was associated with an increased risk of autoimmune disease development (OR 1.62, 95% CI 1.28-2.05). Current antibiotic use was also associated with an increased risk (AOR 1.72, 95% CI 1.07-2.78). A reduced risk of incident autoimmune diseases was observed for current long term users of aminosalicylates (AOR 0.72, 95% CI 0.57-0.91).

Conclusion

Individuals with IBD had an increased incidence of developing a subsequent autoimmune disease. Increased disease severity and current antibiotic use were associated with an increased relative risk of developing additional autoimmune diseases in IBD patients. While, long term current aminosaliylate use was associated with a reduced risk.